Celgene’s Otezla Grabs New Psoriatic Arthritis Patients As Launch Accelerates

Celgene reports its apremilast is attracting more new psoriatic arthritis patients than branded leaders in the space. Sales for its first full quarter amounted to $18 million and new indication in psoriasis should start to contribute later this year, company says.